Skip to main content

Table 1 Baseline characteristics of participants in the MACRO and STATCOPE cohorts

From: Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD

Variable MACRO (n = 976) STATCOPE (n = 653) P*
Age, years 65.5 ± 8.6 62.8 ± 8.4 < 0.001
Gender (Male: Female) – no. (%) 584 (59.8):392 (40.2) 381 (58.3):272(41.7) 0.55
Ethnicity (Caucasian) – no. (%) 806 (82.6) 509 (77.9) 0.02
BMI, kg/m2 27.7 ± 6.2 27.1 ± 6.8 0.062
Current Smokers – no. (%) 207 (21.2) 188 (28.8) < 0.001
FVC, % predicted 70.2 ± 18.1 71.1 ± 19.1 0.29
FEV1, % predicted 39.8 ± 15.7 41.5 ± 17.8 0.049
Long-term oxygen therapy – no. (%) 587 (60.1) 318 (48.7) < 0.001
Systemic steroid use in previous year – no. (%) 822 (84.2) 550 (84.2) 0.99
Inhaled steroid use – no. (%) 764 (78.3) 484 (74.1) 0.06
IgG1 (g/L) 5.09 (2.45) 5.26 (2.70) 0.18
IgG2 (g/L) 2.57 (1.72) 2.61 (1.64) 0.82
IgG3 (g/L) 0.62 (0.49) 0.63 (0.51) 0.96
IgG4 (g/L) 0.21 (0.28) 0.22 (0.32) 0.99
Total IgG (g/L) 8.68 (3.72) 8.84 (4.00) 0.70
  1. Values expressed as means ± SD. IgG levels expressed as median (interquartile range). *Student’s t-test, Mann–Whitney U-test (for comparisons of IgG levels), or Chi-square test, as appropriate. Definition of abbreviations: BMI body mass index, FVC forced vital capacity, FEV1 forced expiratory volume in one second, IgG immunoglobulin G